Table 2.
Leukocytes
| Leukocytes | Median (first quartile, third quartile) |
Statistical analysis (p-value) | |||||
|---|---|---|---|---|---|---|---|
| DUP− | DUP+ | Control | KW test p-value | DUP+ versus DUP− | DUP− versus control | DUP+ versus control | |
| Absolute leukocytes 109/l | 6.64 | 7.3 | 5.64 | 0.040 | < 0.05 | ||
| (5.4, 7.8) | (5.9, 8.6) | (5.25, 7.01) | |||||
| Absolute lymphocytes 109/l | 1.77 | 1.72 | 1.72 | 0.872 | |||
| (1.02, 2.15) | (1.31, 2.55) | (1.43, 1.92) | |||||
| Relative neutrophils, % | 67 | 69 | 54 | 0.010 | 0.062 | < 0.05 | < 0.05 |
| (52, 74.4) | (55, 71.5) | (48.25, 61) | |||||
| Absolute neutrophils 109/l | 4.2 | 4.94 | 3.19 | 0.002 | < 0.05 | < 0.01 | |
| (3.48, 5.23) | (3.6, 5.95) | (2.45, 4.07) | |||||
| Relative monocytes, % | 7.5 | 7.0 | 6.0 | 0.075 | < 0.05 | ||
| (6, 9.75) | (5.5, 9) | 5, 8 | |||||
| Absolute monocytes 109/l | 0.5 | 0.55 | 0.39 | 0.004 | < 0.01 | < 0.05 | |
| (0.39, 0.65) | (0.34, 0.73) | (0.28, 0.47) | |||||
| Relative eosinophils, % | 6.0 | 4.8 | 2.5 | 0.022 | < 0.05 | ||
| (3.35, 8.35) | (2.35, 13.5) | (1.45, 4.72) | |||||
| Absolute eosinophils 109/l | 0.36 | 0.41 | 0.17 | 0.006 | < 0.05 | < 0.05 | |
| (0.16, 0.57) | (0.2, 0.78) | (0.08, 0.25) | |||||
| Relative basophils, % | 0.45 | 0.4 | 0.5 | 0.241 | |||
| (0.3, 0.67) | (0.25, 0.6) | (0.37, 1) | |||||
| Absolute basophils 109/l | 0.025 | 0.03 | 0.03 | 0.523 | |||
| (0.02, 0.05) | (0.02, 0.04) | (0.02, 0,06) | |||||
DUP− patients without dupilumab treatment, DUP+ patients with dupilumab treatment, KW test results of Kruskal–Wallis test. We show the significant difference in statistical analysis, p-value < 0.05